PD19-09 PERFORMANCE OF A NOVEL URINE-BASED BIOMARKER FOR THE MONITORING OF BLADDER CANCER RECURRENCE

Abstract

You have accessJournal of UrologyBladder Cancer: Non-invasive II1 Apr 2017PD19-09 PERFORMANCE OF A NOVEL URINE-BASED BIOMARKER FOR THE MONITORING OF BLADDER CANCER RECURRENCE Ofer Nativ, Sarel Halachmi, Kohava Biton, Marina Zlotnik, Chen Yoffe, Noa Davis, Yael Glickman, and Jacob Bejar Ofer NativOfer Nativ More articles by this author , Sarel HalachmiSarel Halachmi More articles by this author , Kohava BitonKohava Biton More articles by this author , Marina ZlotnikMarina Zlotnik More articles by this author , Chen YoffeChen Yoffe More articles by this author , Noa DavisNoa Davis More articles by this author , Yael GlickmanYael Glickman More articles by this author , and Jacob BejarJacob Bejar More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.882AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The accurate detection of low-grade (LG) urothelial cell carcinoma (UCC) may be challenging, particularly in cases where cytomorphologic features overlap with those of non-neoplastic changes. CellDetect is a unique histochemical stain which enables color discrimination, in addition to morphological examination, for the differentiation between benign and malignant cells in urine specimens. A multi-institutional blinded study has recently shown that this color feature significantly improves the sensitivity for LG tumors when compared to standard urine cytology. The objective of the present study was to confirm this performance in an independent cytology laboratory. METHODS Voided urine samples were collected from a first cohort of patients undergoing routine cystoscopic surveillance. To enrich the study with positive cases, a second cohort of patients scheduled for transurethral resection (TURBT) was also enrolled. The patients from both cohorts had a documented history of bladder cancer. Urine samples were processed into two cytocentrifuge smears and each slide was stained with either CellDetect or standard cytology stain. Both specimens were observed by a cytopathologist blinded to the final diagnosis. The results were then compared to the gold standard (biopsy for positive cases and biopsy or cystoscopy for negative cases). RESULTS 73 patients were enrolled in this study, among which 51 were UCC-negative and 22 UCC-positive. The sensitivity of CellDetect was 82% compared to 59% for standard cytology (p<0.05) while the specificity was not significantly different (86% versus 94%). Moreover, the urine-based biomarker was able to detect 73% of the LG tumors compared to 45% by standard cytology. In addition, it correctly diagnosed 91% of the HG tumors compared to 73% for standard stain. CONCLUSIONS This study validates the usability of CellDetect in clinical settings. Particularly, it confirms its ability to accurately identify UCC recurrence throughout all cancer grades. This could be particularly useful in LG cases where cytomorphologic criteria overlap with benign reactive conditions. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e368 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Ofer Nativ More articles by this author Sarel Halachmi More articles by this author Kohava Biton More articles by this author Marina Zlotnik More articles by this author Chen Yoffe More articles by this author Noa Davis More articles by this author Yael Glickman More articles by this author Jacob Bejar More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...